NO960651L - Farmasöytiske preparater av nervevekstfaktor - Google Patents

Farmasöytiske preparater av nervevekstfaktor

Info

Publication number
NO960651L
NO960651L NO960651A NO960651A NO960651L NO 960651 L NO960651 L NO 960651L NO 960651 A NO960651 A NO 960651A NO 960651 A NO960651 A NO 960651A NO 960651 L NO960651 L NO 960651L
Authority
NO
Norway
Prior art keywords
growth factor
nerve growth
pharmaceutical preparations
lyophilization
admixed
Prior art date
Application number
NO960651A
Other languages
English (en)
Other versions
NO317627B1 (no
NO960651D0 (no
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO960651D0 publication Critical patent/NO960651D0/no
Publication of NO960651L publication Critical patent/NO960651L/no
Publication of NO317627B1 publication Critical patent/NO317627B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19960651A 1993-08-20 1996-02-19 Vandig, farmasoytiske preparater av nervevekstfaktor NO317627B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (3)

Publication Number Publication Date
NO960651D0 NO960651D0 (no) 1996-02-19
NO960651L true NO960651L (no) 1996-02-19
NO317627B1 NO317627B1 (no) 2004-11-29

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960651A NO317627B1 (no) 1993-08-20 1996-02-19 Vandig, farmasoytiske preparater av nervevekstfaktor

Country Status (32)

Country Link
US (2) US6277828B1 (no)
EP (1) EP0721343B1 (no)
JP (2) JP4592830B2 (no)
KR (1) KR100341193B1 (no)
CN (1) CN1163265C (no)
AT (1) ATE226085T1 (no)
AU (1) AU677699B2 (no)
BG (1) BG62951B1 (no)
BR (1) BR9407278A (no)
CA (1) CA2169834C (no)
CZ (1) CZ292422B6 (no)
DE (1) DE69431562T2 (no)
DK (1) DK0721343T3 (no)
ES (1) ES2181723T3 (no)
FI (1) FI113241B (no)
HK (1) HK1012990A1 (no)
HU (1) HU228152B1 (no)
IL (3) IL110725A (no)
LT (1) LT4051B (no)
LV (1) LV11279B (no)
NO (1) NO317627B1 (no)
NZ (1) NZ271873A (no)
PL (1) PL176387B1 (no)
PT (1) PT721343E (no)
RO (1) RO114742B1 (no)
RU (1) RU2126265C1 (no)
SI (1) SI9420048B (no)
SK (1) SK284064B6 (no)
TW (1) TW427905B (no)
UA (1) UA43348C2 (no)
WO (1) WO1995005845A1 (no)
ZA (1) ZA946333B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
JP2001506226A (ja) * 1995-05-12 2001-05-15 ザ ロックフェラー ユニヴァーシティ シナプシンのモジュレーションによるアルツハイマー病の治療法
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
CA2234231C (en) * 1995-11-07 2009-04-14 Genentech, Inc. Stabilizing formulation for ngf
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
DE69836543T2 (de) * 1997-05-01 2007-09-20 Protechtion Unlimited, Inc., Wilmington Nervenwachstumsfaktor als impfstoffadjuvans
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
BR0215216A (pt) * 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
EP2081645B8 (en) * 2006-11-08 2013-07-10 P· MIND Co., Ltd Apparatus for accelerating production of neurotrophic factor
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
BRPI0913684A2 (pt) * 2008-09-26 2015-10-20 Adocia complexo composto por um polissacarídeo substituído por um triptofano ou um derivado de triptofano a partir de uma proteína ligadora à heparina, composição farmacêutica e seus usos
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
EP2694094B1 (en) 2011-04-07 2017-08-16 Neovacs METHOD FOR TREATING IFNalpha RELATED CONDITIONS
WO2013117729A1 (en) * 2012-02-08 2013-08-15 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
EP3287140B1 (en) * 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
ES2893239T3 (es) * 2015-04-21 2022-02-08 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo de inyección
ES2893952T3 (es) * 2015-04-21 2022-02-10 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo para inyección
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
WO2017164349A1 (ja) 2016-03-25 2017-09-28 アステラス製薬株式会社 ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ'フラグメント含有医薬組成物
MX2018014916A (es) * 2016-06-01 2019-07-18 Servier Ip Uk Ltd Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
IL124941A0 (en) 1999-01-26
BR9407278A (pt) 1996-10-01
US7074763B2 (en) 2006-07-11
CA2169834A1 (en) 1995-03-02
EP0721343B1 (en) 2002-10-16
LT96011A (en) 1996-07-25
US6277828B1 (en) 2001-08-21
JPH10508000A (ja) 1998-08-04
PL176387B1 (pl) 1999-05-31
BG62951B1 (bg) 2000-12-29
NO317627B1 (no) 2004-11-29
HU228152B1 (en) 2012-12-28
RU2126265C1 (ru) 1999-02-20
CZ292422B6 (cs) 2003-09-17
RO114742B1 (ro) 1999-07-30
PT721343E (pt) 2003-01-31
BG100371A (bg) 1996-12-31
LV11279B (en) 1996-10-20
SI9420048A (en) 1996-10-31
TW427905B (en) 2001-04-01
CZ42496A3 (en) 1996-05-15
JP2007314572A (ja) 2007-12-06
AU677699B2 (en) 1997-05-01
SK18396A3 (en) 1996-10-02
CN1163265C (zh) 2004-08-25
ES2181723T3 (es) 2003-03-01
LV11279A (lv) 1996-06-20
EP0721343A1 (en) 1996-07-17
AU7566894A (en) 1995-03-21
DK0721343T3 (da) 2003-02-17
PL313084A1 (en) 1996-05-27
KR100341193B1 (ko) 2002-06-21
FI113241B (fi) 2004-03-31
CN1133012A (zh) 1996-10-09
IL110725A (en) 2004-09-27
DE69431562T2 (de) 2003-06-18
CA2169834C (en) 2008-11-04
DE69431562D1 (de) 2002-11-21
HUT74728A (en) 1997-02-28
LT4051B (en) 1996-10-25
HK1012990A1 (en) 1999-08-13
HU9600371D0 (en) 1996-04-29
WO1995005845A1 (en) 1995-03-02
IL110725A0 (en) 1994-11-11
SK284064B6 (sk) 2004-09-08
JP4592830B2 (ja) 2010-12-08
NZ271873A (en) 1996-10-28
FI960750A0 (fi) 1996-02-19
NO960651D0 (no) 1996-02-19
ZA946333B (en) 1996-02-19
FI960750A (fi) 1996-02-20
IL124941A (en) 2006-12-10
SI9420048B (sl) 2003-12-31
US20010007662A1 (en) 2001-07-12
ATE226085T1 (de) 2002-11-15
UA43348C2 (uk) 2001-12-17

Similar Documents

Publication Publication Date Title
NO960651D0 (no) Farmasöytiske preparater av nervevekstfaktor
MX9203439A (es) Una citocina mamifera, il-11
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
AU2789989A (en) Acylated uridine and cytidine and uses thereof
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
AU626033B2 (en) Methods for the treatment and prophylaxis of pneumocystis carinii pneumonia and other diseases and compounds and formulations for use in said methods
DK229387D0 (da) Retinoesyreestere, deres fremstilling og farmaceutiske og kosmetiske praeparater deraf
AU5608798A (en) Formulations of recombinant papillomavirus vaccines
AU2231688A (en) Stabilisation of therapeutically active proteins in a pharmaceutical composition
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
NO911788D0 (no) Galeniske vandige preparater av erytropoietin.
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
DK326985A (da) Farmaceutiske og kosmetiske praeparater indeholdende et anthracenderivat som aktiv bestanddel
IT8921516A0 (it) Procedimento di microincapsulazione di microorganismi vivi e composizioni farmaceutiche stabili.
NO905375L (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
UA30787A (uk) Спосіб лікування хронічного персистуючого гепатиту
NO880412D0 (no) Forblandinger til bruk i akvakultur inneholdende tetracyklin-antibiotika og framgangsmaate for framstilling av slike forblandinger.

Legal Events

Date Code Title Description
MK1K Patent expired